Healthcare Services APAC

APAC Home Infusion Therapy Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

APAC Home Infusion Therapy Market Industry Trends and Forecast to 2034: Segmented by (Therapy, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $3.93 Bn Placeholder estimate
Estimate 2025 $4.29 Bn 19.4% of the global market
Projected 2034 $9.48 Bn 120.8% Adds $5.19 Bn over 9 forecast years
CAGR 2025–2034 9.2% Faster than 36% of 107 Healthcare Services markets here
Key players 5
  • APAC is 19.37% of the global market.
  • Among regions, the largest is North America at $12.37 Bn.
  • Fastest growing: Africa at 9.3% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$5.19 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Home Infusion Therapy Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $3.93 Bn — —
2025 (base) $4.29 Bn +$361.7 Mn —
2026 (forecast) $4.69 Bn +$394.9 Mn +9.2%
2027 (forecast) $5.12 Bn +$431.3 Mn +19.2%
2028 (forecast) $5.59 Bn +$470.9 Mn +30.2%
2029 (forecast) $6.10 Bn +$514.3 Mn +42.2%
2030 (forecast) $6.67 Bn +$561.6 Mn +55.3%
2031 (forecast) $7.28 Bn +$613.2 Mn +69.6%
2032 (forecast) $7.95 Bn +$669.6 Mn +85.2%
2033 (forecast) $8.68 Bn +$731.3 Mn +102.2%
2034 (forecast) $9.48 Bn +$798.5 Mn +120.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Home Infusion Therapy Market Analysis at a glance
Market size, 2025$4.29 Bn placeholder estimate
Forecast, 2034$9.48 Bn placeholder estimate
Growth (CAGR), 2025–20349.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTherapy, product and end user (see all)
Key playersOption Care Health, CVS Health, Optum, Inc., BD (Becton, Dickinson), B. Braun (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Home Infusion Therapy Market Analysis Executive Summary

Home infusion therapy gives intravenous or injected medicines, such as antibiotics and biologics, in the patient's home.

Key segments of the home Infusion Therapy market include therapy (Anti-Infectives, Parenteral Nutrition and Specialty Biologics) and product (Infusion Pumps, Services and Supplies).

Bar chart: Asia Pacific Home Infusion Therapy market size, 2024–2034, placeholder estimates. $3.93 Bn in 2024, $4.29 Bn in 2025 and $9.48 Bn in 2034, 9.2% CAGR.
Asia Pacific Home Infusion Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Home Infusion Therapy Market Dynamics

Market Growth Drivers

Patient demand for care closer to home, staff shortages, lower costs than hospital stays and better remote monitoring technology are driving the home Infusion Therapy market. Payment rules for virtual care have become more supportive.

Opportunity

Hospital-level care at home, chronic disease programs and virtual specialist services give the home Infusion Therapy market strong room to grow.

Market Restraints

Uneven reimbursement, rules on licensing across borders, poor internet in some areas and the need for strong clinical oversight hold back the home Infusion Therapy market.

Competitive Landscape for Home Infusion Therapy Market in APAC

The home Infusion Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Home Infusion Therapy Market in APAC

Home Infusion Therapy in APAC: payment

How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[1], basic medical insurance (China)⁠[2], the Hospital Authority (Hong Kong)⁠[3], Ayushman Bharat PM-JAY (India)⁠[4], public health insurance (Japan)⁠[5], subsidised public care (Malaysia)⁠[6], Pharmac (New Zealand)⁠[7], PhilHealth (Philippines)⁠[8], MediShield Life (Singapore)⁠[9], the Universal Coverage Scheme (Thailand)⁠[10], JKN (BPJS Kesehatan) (Indonesia)⁠[11], out of pocket and Sehat Sahulat (Pakistan)⁠[12], National Health Insurance (South Korea)⁠[13] and social health insurance (Vietnam)⁠[14].

[1] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] Hospital Authority. Checked 14 Nov 2026.

[4] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[5] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[6] Ministry of Health Malaysia. Checked 14 Nov 2026.

[7] Pharmac. Checked 14 Nov 2026.

[8] PhilHealth. Checked 14 Nov 2026.

[9] CPF Board, MediShield Life. Checked 14 Nov 2026.

[10] National Health Security Office. Checked 14 Nov 2026.

[11] BPJS Kesehatan. Checked 19 Nov 2026.

[12] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[13] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[14] Vietnam Social Security. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Licensing, quality standards and payment models from public and private payers shape how home Infusion Therapy services are delivered and paid for in APAC. Government health programs and insurance coverage are key to access.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Home Infusion Therapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Home Infusion Therapy in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Home Infusion Therapy market in Asia Pacific?
Placeholder estimate: about $4.29 Bn in 2025, rising to about $9.48 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Home Infusion Therapy market in Asia Pacific growing?
Placeholder estimate: about 9.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Home Infusion Therapy market report cover?
The report splits the market by therapy (Anti-Infectives, Parenteral Nutrition, Specialty Biologics, Chemotherapy), product (Infusion Pumps, Services, Supplies) and end user (Hospitals, Clinics, Home Care, Corporate and Payer Clients).
Who are the key players in the Home Infusion Therapy market?
Key players include Option Care Health, CVS Health, Optum, Inc., BD (Becton, Dickinson) and B. Braun.
What is driving the Home Infusion Therapy market?
Patient demand for care closer to home, staff shortages, lower costs than hospital stays and better remote monitoring technology are driving the home Infusion Therapy market. Payment rules for virtual care have become more supportive.
How much research is published on Home Infusion Therapy?
PubMed lists 30 papers on Home Infusion Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Healthcare Services reports in APAC

See all

Related on home and long-term care

See the topic